June 21, 2016
1 pm to 2 pm EDT
Sponsored by
Webinar Description:
Personalized Medicine Ex-Oncology – What Are The Up And Coming Key Therapeutic Areas? For the most part, personalized medicine and targeted therapies have been focused on oncology. However, there is new and exciting activity outside of oncology
where biomarker and targeted approaches are proving successful.
Learning Objectives:
- The latest in personalized medicine ex-oncology
- How to prepare for targeted therapy launches
- CI and MR for targeted therapy launches
Speakers:
Peter Keeling
CEO
Diaceutics Group
Peter has over 29 years' experience in international healthcare, first at GSK and Diagnology and then at Diaceutics. Peter has directly initiated and managed the launch of four pharmaceutical, seven OTC and five diagnostic products in addition
to three joint ventures and two major joint corporate marketing campaigns. In addition to Peter's extensive operational experience in the US, he also has substantial experience running operations in all the key healthcare markets of the world,
including Germany, Indonesia the UK and Japan. Since founding Diaceutics, Peter has combined the need for a standardized and structured process to effectively commercialize and launch companion diagnostics alongside drug development with a
group of companies providing customized commercialization services to the pharmaceutical industry Peter has spent two extended periods in applied industrial research, including a year at MIT's Pharmaceutical Program at the Sloan School of
Management in Boston and is considered a thought leader in personalized medicine commercialization.
Steve Vitale, MBA
Managing Director
Diaceutics AIS
With over 20 years' experience, Steve has held several senior roles at GlaxoSmithKline including Innovation Director, US Vaccines, where he spearheaded the creation of the innovation function and drove development of novel services and solutions
to remove barriers customers face throughout the immunization process; Marketing Director, Hib / Meningitis Vaccines, where he launched Hiberix® in the US market and led all pre-commercial and marketing activities supporting the MenHibrix®
launch. Steve also served as Director, Global Commercial Strategy, Cardiovascular / Metabolic where he drove commercial assessments, evolution of product life cycle and market development opportunities for the diabetes franchise. Steve has
recently joined Diaceutics from TGaS Advisors, LLC where he was Head of the TGaS Marketing Benchmark Solution. He has an M.BA. from The Tepper School of Business at Carnegie Mellon University in Pittsburgh, PA and BA in Political Science from
Amherst College in Amherst, MA.
Mark Reis, MBA
EVP Business Development
Diaceutics Group
Mark has spent the past 17 years focused on healthcare business development and marketing at an international level within the pharmaceutical, biotechnology, healthcare informatics and personalized medicine industries. His previous positions at
Medco, DNA Direct, LumaSense Technologies, Inc., Philips Medical Systems, Stentor Inc. and Forbes Medi-tech, included wide-ranging responsibilities from business development, marketing strategy and communications, and sales operations to investor
relations and integrated marketing. Mark holds a Bachelor of Arts from the University of Western Ontario and an M.B.A from New York University Stern School of Business.